Ionis Pharmaceuticals (IONS) Research & Development (2009 - 2026)

Ionis Pharmaceuticals' Research & Development history runs 18 years deep, the most recent figure standing at $210.2 million for Q1 2026.

• On a quarterly basis, Research & Development rose 4.69% year-over-year to $210.2 million in Q1 2026; TTM through Mar 2026 was $925.0 million, a 4.16% increase from a year earlier, with the FY2025 full-year figure at $915.6 million, up 1.56% from the prior year.
• Research & Development fell to $210.2 million in Q1 2026 per IONS's latest filing, from $279.6 million in the prior quarter.
• Across five years, Research & Development topped out at $279.6 million in Q4 2025 and bottomed at -$444.9 million in Q4 2022.
• The 5-year median for Research & Development is $215.3 million (2023), against an average of $176.9 million.
• Across the five-year window, Research & Development soared 157.67% in 2023 and slipped 6.28% in 2025, its largest moves.
• Year by year, Research & Development stood at -$444.9 million in 2022, then surged by 157.67% to $256.6 million in 2023, then dropped by 4.31% to $245.5 million in 2024, then rose by 13.91% to $279.6 million in 2025, then fell by 24.84% to $210.2 million in 2026.
• Per Business Quant, the three latest IONS Research & Development figures stand at $210.2 million (Q1 2026), $279.6 million (Q4 2025), and $217.8 million (Q3 2025).